Latest & greatest articles for lamotrigine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lamotrigine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lamotrigine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lamotrigine

1. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Full Text available with Trip Pro

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the Cochrane Review previously published in 2017.Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss of awareness (...) and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with AS.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other.For the latest update we searched

2019 Cochrane

2. Lamotrigine

Lamotrigine Top results for lamotrigine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lamotrigine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review Full Text available with Trip Pro

Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence (...) in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states. This case reports lamotrigine-induced sexual dysfunction leading to periodic non-adherence.To report lamotrigine-induced sexual dysfunction leading to periodic lamotrigine non-adherence in the context of multiple comorbidities and concurrent antidepressant and antihypertensive pharmacotherapy.Case analysis with PubMed literature review.A 56-year-old male patient with major depression, panic disorder without

2017 BJPsych open

4. Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries Full Text available with Trip Pro

Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries 28546871 2018 11 13 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries. 16036 10.1038/scsandc.2016.36 Almeida Rodrigo L RL Department of Spinal Cord Injury/SARAH Rehabilitation Hospital Network/SARAH Brasilia, Brasilia, Distrito Federal, Brazil. Beraldo Paulo S PS

2017 Spinal cord series and cases

5. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Full Text available with Trip Pro

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the original Cochrane review originally published in 2003, Issue 3, and updated in 2005, Issue 4.Absence seizures are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences (...) are characterised by sudden loss of awareness and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared

2017 Cochrane

6. Lamotrigine

Lamotrigine USE OF LAMOTRIGINE IN PREGNANCY 0344 892 0909 USE OF LAMOTRIGINE IN PREGNANCY (Date of issue: December 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Lamotrigine is an anticonvulsant used either as sole treatment (...) or as adjunctive treatment of focal and generalized seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Lamotrigine is also used in the treatment of bipolar disorder. There is no evidence from studies of over 7,500 exposed pregnancies that use of lamotrigine in the first trimester increases the overall risk of birth defects in the offspring. Although a possible association between first trimester lamotrigine use and orofacial clefting in the infant has been

2014 UK Teratology Information Service

7. Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. (Abstract)

Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. Primary generalized tonic-clonic seizures are one of a number of generalized seizure types which also includes absence, myoclonic and atonic seizures. Effective control of tonic-clonic seizures is required to reduce the risk of injury and death and to improve quality of life. While most people achieve seizure control with one antiepileptic drug, around 30% do not and usually take a combination of antiepileptic (...) drugs.To assess the effectiveness of adjunctive lamotrigine for refractory primary generalized tonic-clonic seizures.We searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE (Ovid) 1950 to June 2010. No language restrictions were imposed. We also contacted GlaxoSmithKline, manufacturers of lamotrigine.Randomised parallel or cross-over add-on trials of add-on lamotrigine for refractory primary generalized tonic-clonic

2010 Cochrane

8. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine

2010 Evidence-Based Mental Health

9. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

10. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Full Text available with Trip Pro

Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Verdian L, Yi Y Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of the addition of rufinamide compared with topiramate or lamotrigine for children with Lennox-Gastaut Syndrome that was uncontrolled by up to three traditional

2010 NHS Economic Evaluation Database.

11. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Full Text available with Trip Pro

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined.In a double-blind, randomized, controlled clinical trial, we compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children (...) with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their demographic characteristics. After 16 weeks of therapy, the freedom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence interval [CI], 0.80 to 1.98; P=0.35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio

2010 NEJM Controlled trial quality: predicted high

12. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

13. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia

Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Article Text Therapeutics Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Statistics from

2009 Evidence-Based Mental Health

14. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine

Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Article Text Therapeutics Combined

2008 Evidence-Based Mental Health

15. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term (...) outcomes, quality of life, and health economic outcomes.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol

2007 Lancet Controlled trial quality: predicted high

16. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Valproate is widely accepted as a drug of first choice for patients with generalised onset seizures, and its broad spectrum of efficacy means it is recommended for patients with seizures that are difficult to classify. Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare (...) the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm B of the study recruited 716 patients for whom valproate was considered to be standard treatment. Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. Primary outcomes

2007 Lancet Controlled trial quality: predicted high

17. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

18. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

19. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder

The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder Calvert N W, Burch S P, Fu A Z, Reeves P, Thompson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several maintenance treatments for adults with bipolar I disorder (BD-I). These were lamotrigine (LAM), lithium (LIT) and olanzapine (OLA). LAM was given at 200 mg/day, LIT at 900 mg/day and OLA at 12.5 mg/day. All treatments were given during the euthymic phase of BD-I for the prevention of episodes

2006 NHS Economic Evaluation Database.

20. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (Abstract)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Absence seizures are brief epileptic seizures which present in childhood and adolescence. They are characterised by sudden loss of awareness and an electroencephalogram (EEG) typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of anticonvulsant (...) for a child with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared with placebo or each other.We searched the Cochrane Epilepsy Group's Specialised Register (March 2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005), MEDLINE (1966 to March 2005) and EMBASE (1988 to March 2005). No language restrictions were imposed

2005 Cochrane